益方生物-U
(688382)
| 流通市值：123.60亿 | | | 总市值：178.13亿 |
| 流通股本：4.01亿 | | | 总股本：5.78亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 8,188,968.92 | 168,790,397.56 | 19,156,299.24 | 14,873,214.62 |
| 营业收入 | 8,188,968.92 | 168,790,397.56 | 19,156,299.24 | 14,873,214.62 |
| 二、营业总成本 | 65,993,855.34 | 410,066,940.31 | 327,620,052.49 | 224,987,384.25 |
| 营业成本 | 1,155,320.93 | 3,923,936.17 | 7,031,049.1 | 6,317,273.35 |
| 税金及附加 | 41,492.19 | 91,684.39 | 70,907.64 | 61,128.69 |
| 管理费用 | 10,411,126.76 | 52,499,006.25 | 43,184,858.85 | 24,297,341.62 |
| 研发费用 | 60,674,466.51 | 384,347,004.37 | 295,676,116.12 | 208,910,699.61 |
| 财务费用 | -6,288,551.05 | -30,794,690.87 | -18,342,879.22 | -14,599,059.02 |
| 其中:利息费用 | 283,229.3 | 664,547.13 | - | - |
| 其中:利息收入 | -6,762,697.62 | 30,021,315.36 | -19,712,098.72 | -14,199,271.32 |
| 加:公允价值变动收益 | 530,000 | 1,300,000 | 830,000 | 260,000 |
| 资产处置收益 | - | 75,015.44 | - | - |
| 信用减值损失(新) | -411,564 | -8,868,360.43 | -4,749,397.83 | -4,540,816.77 |
| 其他收益 | 187,380.26 | 8,566,042.88 | 7,076,641.36 | 176,641.36 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -57,499,070.16 | -240,203,844.86 | -305,306,509.72 | -214,218,345.04 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -57,499,070.16 | -240,203,844.86 | -305,306,509.72 | -214,218,345.04 |
| 六、净利润 | -57,499,070.16 | -240,203,844.86 | -305,306,509.72 | -214,218,345.04 |
| 持续经营净利润 | -57,499,070.16 | -240,203,844.86 | -305,306,509.72 | -214,218,345.04 |
| 归属于母公司股东的净利润 | -57,499,070.16 | -240,203,844.86 | -305,306,509.72 | -214,218,345.04 |
| (一)基本每股收益 | -0.1 | -0.42 | -0.53 | -0.37 |
| (二)稀释每股收益 | -0.1 | -0.42 | -0.53 | -0.37 |
| 八、其他综合收益 | -502,494.69 | -1,159,124.87 | -1,629,834.88 | -984,499.95 |
| 归属于母公司股东的其他综合收益 | -502,494.69 | -1,159,124.87 | -1,629,834.88 | -984,499.95 |
| 九、综合收益总额 | -58,001,564.85 | -241,362,969.73 | -306,936,344.6 | -215,202,844.99 |
| 归属于母公司股东的综合收益总额 | -58,001,564.85 | -241,362,969.73 | -306,936,344.6 | -215,202,844.99 |
| 公告日期 | 2025-04-29 | 2025-04-26 | 2024-10-30 | 2024-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |